

# David D Waters

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3729960/david-d-waters-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66

papers

8,057

citations

27

h-index

89

g-index

99

ext. papers

9,821

ext. citations

8.8

avg, IF

5.53

L-index

#	Paper	IF	Citations
66	Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , <b>2021</b> , 7, 486-495	4.6	18
65	Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons. <i>Circulation</i> , <b>2021</b> , 143, 790-804	16.7	21
64	Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT. <i>Circulation Genomic and Precision Medicine</i> , <b>2021</b> , 14, e003183	5.2	2
63	Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcatrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine. <i>Circulation Genomic and Precision Medicine</i> , <b>2021</b> , 14, e003219	5.2	0
62	Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 924-932	35.1	91
61	Notes From Cardiology Clinic: Brittle Bones and Blue Sclerae. <i>Canadian Journal of Cardiology</i> , <b>2020</b> , 36, 1009-1010	3.8	
60	Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcatrapib. <i>American Heart Journal</i> , <b>2020</b> , 222, 157-165	4.9	10
59	Erratum to "Notes From Cardiology Clinic: The Patients We Dislike": Can J Cardiol 36 (2020) 157-158. <i>Canadian Journal of Cardiology</i> , <b>2020</b> , 36, 965	3.8	
58	HIV infection and coronary heart disease: mechanisms and management. <i>Nature Reviews Cardiology</i> , <b>2019</b> , 16, 745-759	14.8	44
57	Cholesterol Lowering Guidelines: From Whence We Came and Where We Are Now. <i>Canadian Journal of Cardiology</i> , <b>2019</b> , 35, 590-597	3.8	2
56	Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 2497-2505	59.2	861
55	Lipid Abnormalities in Persons Living With HIV Infection. <i>Canadian Journal of Cardiology</i> , <b>2019</b> , 35, 249-259	3.8	17
54	High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study). <i>Metabolism: Clinical and Experimental</i> , <b>2019</b> , 93, 93-99	12.7	10
53	Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. <i>Circulation</i> , <b>2018</b> , 138, 770-781	16.7	65
52	Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	6	1
51	Visit-to-visit variability of lipid measurements as predictors of cardiovascular events. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 356-366	4.9	26
50	Variations in time to benefit among clinical trials of cholesterol-lowering drugs. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 857-862	4.9	13

49	Lipids, inflammation, and chronic kidney disease: a SHARP perspective. <i>Kidney International</i> , <b>2018</b> , 93, 784-786	9.9	2
48	Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 130-136	4.9	27
47	RE: Praluent (Alirocumab)-Induced Renal Injury. <i>Journal of Pharmacy Practice</i> , <b>2018</b> , 31, 138-139	1.3	1
46	Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2018</b> , 11, e004724	5.8	27
45	PCSK9 Inhibition to Reduce Cardiovascular Risk: Tempering Expectations. <i>Circulation Research</i> , <b>2017</b> , 120, 1537-1539	15.7	8
44	Body-Weight Fluctuations and Outcomes in Coronary Disease. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1332-1340	59.2	150
43	An Evidence-Based Guide to Cholesterol-Lowering Guidelines. <i>Canadian Journal of Cardiology</i> , <b>2017</b> , 33, 343-349	3.8	13
42	Are Cholesterol Treatment Targets a Deterrent to Optimal Lipid-Lowering Therapy?. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 1392-1393	16.2	1
41	Body-Weight Fluctuations and Outcomes in Coronary Disease. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 95-6	59.2	10
40	Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial. <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 379-387	3	41
39	Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study). <i>American Journal of Cardiology</i> , <b>2016</b> , 118, 494-8	3	4
38	2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 384-91	2.4	26
37	Statin-centric versus low-density lipoprotein-centric approach for atherosclerotic cardiovascular disease prevention: a Singapore perspective. <i>Singapore Medical Journal</i> , <b>2016</b> , 57, 360-7	1.9	5
36	Metabolic Markers to Predict Incident Diabetes Mellitus in Statin-Treated Patients (from the Treating to New Targets and the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trials). <i>American Journal of Cardiology</i> , <b>2016</b> , 118, 1275-1281	3	9
35	The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. <i>European Heart Journal</i> , <b>2015</b> , 36, 1536-46	9.5	88
34	PCSK9 Inhibition to Lower LDL-Cholesterol and Reduce Cardiovascular Risk: Great Expectations. <i>Circulation Research</i> , <b>2015</b> , 116, 1643-5	15.7	4
33	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet, The</i> , <b>2015</b> , 385, 351-61	40	409
32	LDL-cholesterol lowering and renal outcomes. <i>Current Opinion in Lipidology</i> , <b>2015</b> , 26, 195-9	4.4	10

31	Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials. <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 447-53	3	33
30	Cardiovascular drugs that increase the risk of new-onset diabetes. <i>American Heart Journal</i> , <b>2014</b> , 167, 421-8	4.9	18
29	Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 1378-82	3	21
28	Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 485-94	15.1	372
27	Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials. <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 2018-20 <sup>3</sup>		32
26	Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study). <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 1593-8	3	22
25	Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. <i>PLoS ONE</i> , <b>2014</b> , 9, e114519	3.7	34
24	The past and future of heart institutes: having moved beyond the one-trick pony. <i>Canadian Journal of Cardiology</i> , <b>2014</b> , 30, S478-82	3.8	3
23	Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 148-52	15.1	130
22	Utility of biomarkers and imaging in the development of drugs for the treatment of coronary atherosclerosis. <i>Canadian Journal of Cardiology</i> , <b>2012</b> , 28, 687-92	3.8	1
21	Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 57, 1535-45	15.1	259
20	Exploring new indications for statins beyond atherosclerosis: Successes and setbacks. <i>Journal of Cardiology</i> , <b>2010</b> , 55, 155-62	3	18
19	Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. <i>Circulation</i> , <b>2009</b> , 120, 28-34	16.7	253
18	Clinical insights from the Treating to New Targets trial. <i>Progress in Cardiovascular Diseases</i> , <b>2009</b> , 51, 487-502	8.5	5
17	Early statin therapy in acute coronary syndromes: the successful cycle of evidence, guidelines, and implementation. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, 1434-7	15.1	22
16	Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2008</b> , 28, 142-7	9.4	57
15	TNT Trial <b>2008</b> , 1		
14	Effects of torcetrapib in patients at high risk for coronary events. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 2109-22	59.2	2323

13	Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. <i>Aids</i> , <b>2006</b> , 20, 2275-83	3.5	213
12	Safety of high-dose atorvastatin therapy. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 69F-75F	3	51
11	Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. <i>American Journal of Cardiology</i> , <b>2004</b> , 93, 154-8	3	151
10	Statins and safety: applying the results of randomized trials to clinical practice. <i>American Journal of Cardiology</i> , <b>2003</b> , 92, 692-5	3	10
9	Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 288, 49-57	27.4	1150
8	Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. <i>Circulation</i> , <b>2002</b> , 106, 1690-5	16.7	156
7	Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 288, 2432-40	27.4	389
6	What do the statin trials tell us?. <i>Clinical Cardiology</i> , <b>2001</b> , 24, III3-7	3.3	6
5	The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins?. <i>Current Controlled Trials in Cardiovascular Medicine</i> , <b>2001</b> , 2, 111-114		17
4	Low-Density-Lipoprotein Cholesterol Goals for Patients With Coronary Disease. <i>Circulation</i> , <b>2001</b> , 104, 2635-2637	16.7	5
3	Postscripts from the Post-Coronary Artery Bypass Graft trial: the sustained benefit of more aggressive cholesterol lowering and the enigma of low-dose anticoagulation. <i>Circulation</i> , <b>2000</b> , 102, 144-6	16.7	9
2	Cholesterol lowering. Should it continue to be the last thing we do?. <i>Circulation</i> , <b>1999</b> , 99, 3215-7	16.7	25
1	Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. <i>Circulation</i> , <b>1995</b> , 91, 2132-9	16.7	80